A osteoarthritis (OA) is the most common osteoarticular disease, mainly, in large dogs, affecting more than 20% of dogs over one year old.
Treatments that directly address the cause of joint pain in dogs are scarce on the market., the majority being directed towards the use of anti-inflammatories that, with time, cause severe kidney impairment, liver, pet's stomach and general health. TO PETAG® was developed by Gelita, through innovation, as a beneficial alternative.
The effect of TO PETAG® has been analyzed and approved in several preclinical studies and clinical trials. Always administered orally, TO PETAG® is partially absorbed as intact peptides.
These bioactive collagen peptides stimulate cartilage cells (chondrocytes) to increase the production of a new cartilaginous matrix.
This cartilage matrix consists of, predominantly, in collagen and proteoglycans that act as a buffer between bones.
To prove its effects, a study carried out with 26 German Shepherd dogs, aimed to evaluate the progression of lameness (act of missing) and increasing difficulties in moving, during 12 weeks with administration of 5g per day of TO PETAG® via oral.
With supplementation, lameness was reduced and the ability to move (getting up and climbing stairs) significantly improved in 70% of dogs, demonstrating a regression of the disease.
In elderly animals, the benefits of TO PETAG® are diverse: increased activity, regaining mobility and flexibility and, like this, improving animal welfare.
In active animals, becomes an excellent mobility and flexibility support, optimizing health, joint function and comfort, assisting in the performance of daily exercises.
TO PETAG® It is an innovative product, easy to handle and provides excellent solubility. In its formulation, does not contain fat, purines, cholesterol, additives, synthetic dyes and aromas.
With a palatability test in dogs, TO PETAG® showed great acceptance.
Get in touch with Tovani Benzaquen and learn more about this innovative ingredient from Gelita for the health of pets!